AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11212979 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg (in ISH subgroup)
Number of subjects: 524
Study 11212979 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg (in ISH subgroup)
Number of subjects: 524
Study 11212979 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (in ISH subgroup)
Number of subjects: 524
Study 11212979 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (in ISH subgroup)
Number of subjects: 524
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI 100 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI 200 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI 400 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI 800 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Turbuhaler 50 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Turbuhaler 100 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9707454 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol pMDI 200 microg vs pMDI 100 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol pMDI 200 microg vs Turbuhaler 100 microg
Number of subjects: 23
Study 9707454 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol pMDI 200 microg vs pMDI 400 microg
Number of subjects: 23
Study 9371301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin administered using a validated protocol
Number of subjects: 0
Study 9371301 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive strategy for patients with clinically suspected pulmonary embolism
Number of subjects: 0
Study 2701030 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline 200 mg sachets, administered at a daily dose of 12 mg/kg for 14 days.
Number of subjects: 11
Study 2701030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1139016 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (using BH onset as an unconditioned stimulus)
Number of subjects: 0
Study 31939496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% DOX + scaling and root planning (SRP)
Number of subjects: 33
Study 31939496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% DOX /β‐CD + SRP
Number of subjects: 33
Study 31939496 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 33
Study 31278695 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 351
Study 31278695 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined thresholds of synovitis ≤3, osteitis ≤3, and total inflammation score ≤9
Number of subjects: 351
Study 28843636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 22
Study 28843636 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 22
Study 25995511 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Professional Development (CPD) training
Number of subjects: 72
Study 25995511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 23929928 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (80 mg)
Number of subjects: 99
Study 23929928 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg)
Number of subjects: 99
Study 23929928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 22178829 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone treatment group
Number of subjects: 92
Study 22178829 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle adjustment group
Number of subjects: 92
Study 22178829 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance group (Group B)
Number of subjects: 92
Study 22178829 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes group (Group C)
Number of subjects: 92
Study 19368508 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based dietary intervention (Coronary Health Improvement Project)
Number of subjects: 0
Study 16238680 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin or simvastatin therapy
Number of subjects: 134
Study 12094118 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right (BR) external nasal dilator
Number of subjects: 10
Study 12094118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal nasal ventilation (N)
Number of subjects: 10
Study 12094118 — intervention group
Group type: COMPARATOR
Intervention: No nasal ventilation (using a nose clip) (NC)
Number of subjects: 10
Study 10210737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (2 effervescent tablets of 400 mg)
Number of subjects: 600
Study 10210737 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (2 effervescent tablets of 500 mg)
Number of subjects: 600
Study 10210737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 effervescent tablets)
Number of subjects: 600
Study 7597268 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 26
Study 7597268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1708032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234
Study 1708032 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study 295279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg for one week
Number of subjects: 22
Study 295279 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one week
Number of subjects: 22
Study 31126887 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 120
Study 31126887 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 120
Study 31126887 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 120
Study 31126887 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 120
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in the waiting room
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse time with the patient
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician time with the patient
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Total time for a PC encounter
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting wait times
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting clinician time
Number of subjects: 36437
Study 27375293 — intervention group
Group type: EXPERIMENTAL
Intervention: Late check-in and same-day visits
Number of subjects: 36437
Study 25773354 — intervention group
Group type: EXPERIMENTAL
Intervention: FE 999049 (rFSH) administered subcutaneously at doses of 37.5, 75, 150, 225, or 450 IU
Number of subjects: 79
Study 25773354 — intervention group
Group type: EXPERIMENTAL
Intervention: FE 999049 (rFSH) administered subcutaneously
Number of subjects: 79
Study 23379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (60 ppb) in persistent asthmatic children with low vitamin C intake and GSTM1 null genotype
Number of subjects: 257
Study 23379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (60 ppb) in persistent asthmatic children with 4 to 6 risk alleles and low vitamin C intake
Number of subjects: 257
Study 23379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (60 ppb) in children with 1 to 3 risk alleles
Number of subjects: 257
Study 22278799 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull Grip
Number of subjects: 16
Study 22278799 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures (Prolene 0.0)
Number of subjects: 16
Study 19439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry air chilling (AC) at 0.7 degrees C for 150 min
Number of subjects: 108
Study 19439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion chilling (IC) at 0.3 degrees C for 50 min
Number of subjects: 108
Study 19439641 — intervention group
Group type: COMPARATOR
Intervention: No chilling (immediate removal upon arrival)
Number of subjects: 108
Study 17373904 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-β1a
Number of subjects: 0
Study 15473455 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-diameter pan (220 mm)
Number of subjects: 20
Study 15473455 — intervention group
Group type: COMPARATOR
Intervention: Small-diameter pan (165 mm)
Number of subjects: 20
Study 11573637 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinase-modified thrombelastography algorithm
Number of subjects: 60
Study 11573637 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria and laboratory-based tests
Number of subjects: 60
Study 11573637 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm group
Number of subjects: 60
Study 11573637 — intervention group
Group type: COMPARATOR
Intervention: Clinically managed group
Number of subjects: 60
Study 9577233 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection policies with merit considerations central to decision-making (Study 1)
Number of subjects: 225
Study 9577233 — intervention group
Group type: COMPARATOR
Intervention: Selection policies without clear merit considerations (Study 2)
Number of subjects: 225
Study 9577233 — intervention group
Group type: COMPARATOR
Intervention: Work-related reactions of nonbeneficiaries (Study 3)
Number of subjects: 225
Study 8161957 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced operator
Number of subjects: 0
Study 8161957 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced operator
Number of subjects: 0
Study 8161957 — intervention group
Group type: COMPARATOR
Intervention: Measurement procedure
Number of subjects: 0
Study 8161957 — intervention group
Group type: COMPARATOR
Intervention: Day-to-day variations within subjects
Number of subjects: 0
Study 8161957 — intervention group
Group type: COMPARATOR
Intervention: Inter-subject differences
Number of subjects: 0
Study 3202132 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) 300 mg daily for 4 weeks
Number of subjects: 128
Study 3202132 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 36 mg daily for 4 weeks
Number of subjects: 128
Study 30608607 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Sure (online decision support aid)
Number of subjects: 93
Study 30608607 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 28983961 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 levels measured using MiniVol samplers for a period of 24 hours.
Number of subjects: 0
Study 28983961 — intervention group
Group type: EXPERIMENTAL
Intervention: Household characteristics and activities (crowding, dwelling type, household emissions from incense, candles, cooking, and household smoking practices).
Number of subjects: 0
Study 28983961 — intervention group
Group type: EXPERIMENTAL
Intervention: Room magnitude and natural ventilation factors.
Number of subjects: 0
Study 28983961 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for PM2.5 levels.
Number of subjects: 0
Study 27829405 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development for educators to reduce sitting time during ECEC services
Number of subjects: 0
Study 27829405 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25896182 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 10 g daily for 12 weeks
Number of subjects: 15
Study 25896182 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO) 10 g daily for 12 weeks
Number of subjects: 15
Study 25896182 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO)
Number of subjects: 15
Study 23594410 — intervention group
Group type: EXPERIMENTAL
Intervention: Houvast (strengths based method)
Number of subjects: 251
Study 23594410 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 251
Study 20940193 — intervention group
Group type: EXPERIMENTAL
Intervention: Full screening (DT, problem checklist, Psychological Screen for Cancer part C, personalized report, report on medical file)
Number of subjects: 1134
Study 20940193 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage (full screening plus optional personalized phone triage)
Number of subjects: 1134
Study 20940193 — intervention group
Group type: COMPARATOR
Intervention: Minimal screening (DT only plus usual care)
Number of subjects: 1134
Study 18773724 — intervention group
Group type: EXPERIMENTAL
Intervention: Offsetting the stripes in the window
Number of subjects: 0
Study 18773724 — intervention group
Group type: COMPARATOR
Intervention: Manipulating the outline (no outline, black outline, red outline)
Number of subjects: 0
Study 18773724 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-stripe offset manipulation
Number of subjects: 0
Study 16025252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4458
Study 16025252 — intervention group
Group type: COMPARATOR
Intervention: Metformin or Sulphonylurea (non-rosiglitazone group)
Number of subjects: 4458
Study 12500996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockport one‐mile walk test equation
Number of subjects: 304
Study 12500996 — intervention group
Group type: EXPERIMENTAL
Intervention: New regression model for predicting peak oxygen uptake (VO2peak) from a one‐mile treadmill walk
Number of subjects: 304
Study 10515287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg)
Number of subjects: 0
Study 7746913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium vaccae
Number of subjects: 0
Study 7746913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chemotherapy alone)
Number of subjects: 0
Study 2139286 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine alone (10 micrograms)
Number of subjects: 58
Study 2139286 — intervention group
Group type: COMPARATOR
Intervention: Recombinant DNA hepatitis B vaccine + hepatitis B immune globulin (HBIg) (10 micrograms + 0.5 ml HBIg)
Number of subjects: 58
Study 6993109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadiazine 225 mg and Trimethoprim 75 mg (SD/TMP)
Number of subjects: 200
Study 6993109 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethoxazole 400 mg and Trimethoprim 80 mg (SM/TMP)
Number of subjects: 200
Study 30982549 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stent diameter (SD ≤ 2.75 mm)
Number of subjects: 6413
Study 30982549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate stent diameter (2.75 mm < SD ≤ 3.25 mm)
Number of subjects: 6413
Study 30982549 — intervention group
Group type: EXPERIMENTAL
Intervention: Large stent diameter (SD ≥ 3.25 mm)
Number of subjects: 6413
Study 30982549 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-generation drug-eluting stents (DES)
Number of subjects: 6413
Study 30982549 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 6413
Study 28844494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal corticosteroids (NCS) for 12 weeks
Number of subjects: 82
Study 28844494 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) application
Number of subjects: 82
Study 26298752 — intervention group
Group type: EXPERIMENTAL
Intervention: endurance training + kefir beverage
Number of subjects: 67
Study 26298752 — intervention group
Group type: COMPARATOR
Intervention: endurance training + control beverage
Number of subjects: 67
Study 26298752 — intervention group
Group type: EXPERIMENTAL
Intervention: active control + kefir beverage
Number of subjects: 67
Study 26298752 — intervention group
Group type: COMPARATOR
Intervention: active control + control beverage
Number of subjects: 67
Study 23648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite administration prior to percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 23648219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite administration
Number of subjects: 0
Study 21663644 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA isolation using QIAGEN automated protocols, specifically the Compromised Blood Protocol
Number of subjects: 120
Study 21663644 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of participant at blood draw
Number of subjects: 120
Study 21663644 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA quality assessment via gel electrophoresis QC and TaqMan genotyping
Number of subjects: 120
Study 19539142 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 25), 3 visits/week for 3 months
Number of subjects: 50
Study 19539142 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 19539142 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 25)
Number of subjects: 50
Study 18604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 15/minute)
Number of subjects: 60
Study 18604045 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 12/minute)
Number of subjects: 60
Study 14999362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahaler (3 mg)
Number of subjects: 12
Study 14999362 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer (3 mg)
Number of subjects: 12
Study 11682390 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and ketamine (Group A: 16.67 microg x kg(‐1) x min(‐1) for 30 min, 13.3 microg x kg(‐1) x min(‐1) for 90 min, then 10 microg x kg(‐1) x min(‐1); Group B: 8.33 microg x kg(‐1) x min(‐1) for 30 min, 6.67 microg x kg(‐1) x min(‐1) for 90 min, then 5 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 11682390 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and ketamine (Group A)
Number of subjects: 60
Study 10611198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system of ascites (CATSA) performed for 5 hours at a rate of 100-200 ml/h once a day
Number of subjects: 54
Study 10611198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system of ascites (CATSA)
Number of subjects: 54
Study 10611198 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albumin supplement (37.5 g/day)
Number of subjects: 54
Study 9189783 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexercise carbohydrate (CHO) feedings (22.5, 45, or 75 g maltodextrin and dextrose in 473 ml of water)
Number of subjects: 8
Study 9189783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 9189783 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexercise carbohydrate (CHO) feedings
Number of subjects: 8
Study 1555806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin gel preparation 1
Number of subjects: 0
Study 1555806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin gel preparation 2
Number of subjects: 0
Study 1555806 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or alternative treatment not specified)
Number of subjects: 0
Study 2581308 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 54
Study 2581308 — intervention group
Group type: COMPARATOR
Intervention: amidotrizoate
Number of subjects: 54
Study 30064731 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive psychiatric consultation
Number of subjects: 2177
Study 30064731 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2177
Study 26780289 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse to injecting drug use (IDU) after treatment
Number of subjects: 161
Study 26780289 — intervention group
Group type: EXPERIMENTAL
Intervention: History of IDU prior to treatment
Number of subjects: 161
Study 24275909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 20 sessions over 5 months
Number of subjects: 70
Study 24275909 — intervention group
Group type: COMPARATOR
Intervention: Psychoanalytic psychotherapy, 2 years of weekly sessions
Number of subjects: 70
Study 22697453 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), n=26
Number of subjects: 37
Study 22697453 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC), n=11
Number of subjects: 37
Study 20693439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip and palm (N = 41)
Number of subjects: 84
Study 20693439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip and forearm (N = 40)
Number of subjects: 84
Study 20693439 — intervention group
Group type: COMPARATOR
Intervention: Fingertip
Number of subjects: 84
Study 20693439 — intervention group
Group type: COMPARATOR
Intervention: Forearm
Number of subjects: 84
Study 20693439 — intervention group
Group type: COMPARATOR
Intervention: Palm
Number of subjects: 84
Study 18831899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 28
Study 18831899 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 28
Study 16134133 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug (low and high dose)
Number of subjects: 0
Study 16134133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Preirradiation chemotherapy (2 cycles of ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine), n = 40
Number of subjects: 63
Study 11821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after irradiation (8 cycles with cisplatin, vincristine, and lomustine), n = 23
Number of subjects: 63
Study 11821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation (total dose of 35.2 Gy followed by a boost of 20.0 Gy to the primary tumor site), n = 54
Number of subjects: 63